6:12 PM
 | 
Feb 13, 2013
 |  BC Extra  |  Clinical News

Medivation, Astellas report hormone-naïve prostate cancer data

Medivation Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. (Tokyo:4503) said once-daily oral Xtandi enzalutamide met the primary endpoint in an open-label Phase II trial in 67 patients with hormone-naïve prostate cancer. Specifically, 93% of patients receiving Xtandi had a...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >